Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

15.780
+0.6304.16%
Volume:27.80M
Turnover:440.09M
Market Cap:17.89B
PE:-12.56
High:16.200
Open:15.570
Low:15.500
Close:15.150
52wk High:35.500
52wk Low:12.310
Shares:1.13B
HK Float Shares:1.13B
Volume Ratio:2.55
T/O Rate:2.45%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.256
ROE:-22.56%
ROA:-12.16%
PB:3.19
PE(LYR):-12.56
PS:4.96

Loading ...

HK Stock Connect Shareholding Changes | November 12

Stock News
·
Nov 12, 2025

Zai Lab (9688) Announces Grants of Share Options and Restricted Share Units Under Equity Plan

Bulletin Express
·
Nov 11, 2025

Zai Lab (09688) Grants Stock Options and Restricted Share Units

Stock News
·
Nov 11, 2025

Vertex Reports 64% Proteinuria Reduction With Povetacicept in IgA Nephropathy Trial

Reuters
·
Nov 10, 2025

Hong Kong Stock Short Interest Data as of November 7

Stock News
·
Nov 07, 2025

Hong Kong Stock Connect Innovative Drug Sector Declines in Afternoon Session, Zai Lab Plunges 10%, 520880 Drops 2% Below 10-Day Moving Average, Intraday Premium Surges

Deep News
·
Nov 07, 2025

Zai Lab's Q3 Loss Narrows as Revenue Jumps 14%; Shares Fall 8%

MT Newswires Live
·
Nov 07, 2025

Stock Track | Zai Lab Plummets 7.49% as Q3 Earnings Miss Expectations

Stock Track
·
Nov 07, 2025

Stock Track | ZAI LAB Plummets 7.49% as Q3 Earnings Miss Estimates, Revenue Falls Short

Stock Track
·
Nov 07, 2025

HK Stock Announcement Highlights | GALAXY ENT Q3 Net Revenue Rises 14% YoY to HK$12.2B

Stock News
·
Nov 06, 2025

Zai Lab (09688) Reports 14% YoY Revenue Growth in Q3, Totaling $116.1 Million

Stock News
·
Nov 06, 2025

Zai Lab Raises 2025 Revenue Guidance to At Least $460 Million

Reuters
·
Nov 06, 2025

Zai Lab Ltd: Revising Total Revenue Guidance for Full Year 2025 to at Least $460 Mln

THOMSON REUTERS
·
Nov 06, 2025

Zai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy

MT Newswires Live
·
Nov 05, 2025

BRIEF-Zai Lab Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

Reuters
·
Nov 05, 2025

Zai Lab (09688) Provides Update on Amgen's Bemarituzumab Phase 1b/3 FORTITUDE-102 Clinical Trial

Stock News
·
Nov 05, 2025

Zai Lab Reports Amgen Halts Phase 1b/3 FORTITUDE-102 Trial for Bemarituzumab in Gastric Cancer

Reuters
·
Nov 05, 2025

Zai Lab Ltd - Update on Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

THOMSON REUTERS
·
Nov 05, 2025

Zai Lab CFO Yajing Chen Reports Disposal of Common Shares

Reuters
·
Nov 05, 2025

Zai Lab Ltd expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025